Skip to Content

Posts tagged with "Drug Industry History"

  • Business and Markets

    The Baseless Fabric of This Vision

    Not everyone is going to sit still and listen to someone from GlaxoSmithKline talk about how to most effectively deploy chemists (and wonder where more of them might be coming from). If you’re up for it, here’s the article at Drug Discovery Today. It’s not trying to hide the situation, though (links added for the original… Read More
  • Cardiovascular Disease

    CETP Finally Heads to the Trash Heap?

    The tale of CETP (cholesteryl ester transfer protein) as a drug target has been long, and convoluted, and expensive, and horrendously disappointing. Pfizer failed, Roche failed, several other companies like BMS who didn’t even get that far failed, and last fall Lilly’s entry failed, too (that link has links to several past blog posts he… Read More
  • Drug Development

    The Puritan Impulse

    Here’s a good blog post with a lot of food for thought, and here’s the follow-up. I missed these back when they came out last year, but the issues they raise are (for better or worse) evergreen. The author’s framing a debate about medicinal chemistry as Cavaliers-versus-Roundheads, which is a classification that’s useful en… Read More
  • Animal Testing

    A Terrific Paper on the Problems in Drug Discovery

    Here’s a really interesting paper from consultants Jack Scannell and Jim Bosley in PLoS ONE, on the productivity crisis in drug discovery. Several things distinguish it: for one, it’s not just another “whither the drug industry” think piece, of which we have plenty already. This one get quantitative, attempting to figure out… Read More
  • Academia (vs. Industry)

    Drugs Purely From Academia

    I see that there’s an investment fund in Europe saying that “Every year, around 30 to 40 percent of the drugs approved by the FDA (U.S. Food and Drug Administration) were actually discovered in European academic labs“. Meanwhile the European Medicines Agency says that “Academia and other public-private partnerships helped to… Read More
  • Business and Markets

    Compassion, Drug Prices, and Money

    A number of people have sent along this article from The Guardian. It’s about Jamie Love, a campaigner for cheaper pharmaceuticals. It’s a long, well-written piece, and I’ll summarize it only by saying that Love is very much opposed to the patent system, is very much a fan of compulsory licensing, and is clearly very… Read More
  • Business and Markets

    Pfizer Versus BMS, Since 1989

    I very much enjoyed this piece by Bernard Munos on Pfizer. It follows the same method as this classic article by Matthew Herper (updated here, commented on here and here): If you want to figure out how much a company is spending per new drug, take a reasonably long period, add up all the R&D… Read More
  • Business and Markets

    Pfizer: One Step Ahead of the Mudslide

    Mentioning Pfizer/Allergan prompts me to strongly recommend this post by Bernard Munos: “Pfizer Does Not Need a Merger – It Needs a Rebellion”. He takes the long view, and the long view here is not pretty. Over the last ten or fifteen years, you’d have been better owning the S&P than Pfizer (and yes, that… Read More
  • Drug Development

    The Economist’s Take On Drug Discovery

    The Economist has one of those articles that makes a person wonder. It’s a long-remarked phenomenon that whenever a newspaper writes about something that you really know, the omissions and inaccuracies that show up should make you uneasy about their coverage of everything else. And so it is here, unfortunately. The hook for the piece… Read More
  • Chemical News

    Boring! Or: The Medicinal Chemist’s Toolkit

    There’s a new paper out on a topic that is of great interest for medicinal chemists: what sort of chemistry is it that we’re spending all our time doing? It’s a study of the literature from 1984 to 2014, analyzed by reaction type and other factors, and here’s the take-home: “. . .of the current… Read More
...456...